Cancer killing virus shows promise for liver cancer
Nature Medicine
2013년2월11일
Evidence of a dose dependent therapeutic effect from the JX-594 virus that infects and kills tumor cells in patients with advanced liver cancer is reported in a study published online this week in Nature Medicine.
JX-594 is a modified vaccinia virus. While Phase 1 studies had been performed using the virus, David Kirn and colleagues report the first dose-finding study of JX-594 and evidence that it can induce antitumor immune responses. The authors found that for patients with hepatocellular carcinoma (HCC) that received the high dose of virus, median survival was 14.1 months, compared with 6.7 months for patients receiving the low dose arm.
These results must be confirmed in larger placebo controlled trials and further studies will be necessary to fully ascertain the mechanisms of protective efficacy of JX-594, though these results do offer hope for a new approach to tumor treatment.
doi: 10.1038/nm.3089
리서치 하이라이트
-
7월1일
Criminology: Predicting police enforcement bias in major US citiesNature Human Behaviour
-
7월1일
Space health: The path of most resistance could help limit bone loss during spaceflightScientific Reports
-
6월30일
Microbiology: Transmission of gastrointestinal viruses in salivaNature
-
6월29일
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
6월24일
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature